{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T12:07:58Z","timestamp":1795090078907,"version":"4.10.2"},"reference-count":20,"publisher":"BMJ","issue":"4","funder":[{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","award":["no award\/grant number"],"award-info":[{"award-number":["no award\/grant number"]}],"id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Association pulmonaire du Qu\u00e9bec","award":["no award\/grant number"],"award-info":[{"award-number":["no award\/grant number"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Thorax"],"accepted":{"date-parts":[[2024,1,29]]},"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1136\/thorax-2023-221274","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T18:25:55Z","timestamp":1708021555000},"page":"297-298","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Blood eosinophils take centre stage in predicting the response to sublingual immunotherapy (SLIT): a familiar twist"],"prefix":"10.1136","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8405-4513","authenticated-orcid":false,"given":"Carlos Andr\u00e9s","family":"Celis-Preciado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Lachapelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4057-6886","authenticated-orcid":false,"given":"Simon","family":"Couillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,2,15]]},"reference":[{"key":"2025042101250959000_79.4.297.1","article-title":"Sublingual immunotherapy for asthma","volume":"9","author":"Fortescue","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"2025042101250959000_79.4.297.2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.3964"},{"key":"2025042101250959000_79.4.297.3","unstructured":"Global Initiative for Asthma (GINA) . Global strategy for asthma management and prevention (2023 update). 2023. Available: https:\/\/ginasthma.org\/"},{"key":"2025042101250959000_79.4.297.4","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0114-2020"},{"key":"2025042101250959000_79.4.297.5","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2023-221274"},{"key":"2025042101250959000_79.4.297.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.02.012"},{"key":"2025042101250959000_79.4.297.7","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1164\/rccm.202104-1040LE","article-title":"Fractional exhaled nitric oxide nonsuppression identifies corticosteroid-resistant Type 2 signaling in severe asthma","volume":"204","author":"Couillard","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2025042101250959000_79.4.297.8","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/j.chest.2021.07.008","article-title":"How I do It. Work-up of severe asthma","volume":"160","author":"Couillard","year":"2021","journal-title":"Chest"},{"key":"2025042101250959000_79.4.297.9","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201208-1414OC"},{"key":"2025042101250959000_79.4.297.10","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jaip.2018.04.043","article-title":"Omalizumab effectiveness by biomarker status in patients with asthma: evidence from PROSPERO, a prospective real-world study","volume":"7","author":"Casale","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025042101250959000_79.4.297.11","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.anai.2017.12.002","article-title":"Thunderstorm asthma: an allergen-induced early asthmatic response","volume":"120","author":"Cockcroft","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2025042101250959000_79.4.297.12","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/j.jaci.2021.10.028","article-title":"Thunderstorm asthma in seasonal allergic rhinitis: the TAISAR study","volume":"149","author":"Douglass","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"2025042101250959000_79.4.297.13","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01359-2015"},{"key":"2025042101250959000_79.4.297.14","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2021-217325"},{"key":"2025042101250959000_79.4.297.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30879-6"},{"key":"2025042101250959000_79.4.297.16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1183\/23120541.00570-2021","article-title":"Predicting the benefits of type-2 targeted anti-inflammatory treatment with the prototype Oxford Asthma Attack Risk Scale (ORACLE)","volume":"8","author":"Couillard","year":"2022","journal-title":"ERJ Open Res"},{"key":"2025042101250959000_79.4.297.17","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00220413"},{"key":"2025042101250959000_79.4.297.18","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-2600(17)30344-2","article-title":"Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies","volume":"6","author":"FitzGerald","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2025042101250959000_79.4.297.19","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2147\/JAA.S385645","article-title":"Dupilumab efficacy in patients with uncontrolled moderate-to-severe type 2 asthma regardless of perennial aeroallergen sensitization","volume":"16","author":"Corren","year":"2023","journal-title":"J Asthma Allergy"},{"key":"2025042101250959000_79.4.297.20","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1164\/rccm.202210-2005OC","article-title":"Efficacy of Tezepelumab in severe, uncontrolled asthma: pooled analysis of the PATHWAY and NAVIGATOR clinical trials","volume":"208","author":"Corren","year":"2023","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Thorax"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/thorax-2023-221274","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T10:59:45Z","timestamp":1745233185000},"score":1,"resource":{"primary":{"URL":"https:\/\/thorax.bmj.com\/lookup\/doi\/10.1136\/thorax-2023-221274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,15]]},"references-count":20,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,3,15]]},"published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1136\/thorax-2023-221274"],"URL":"https:\/\/doi.org\/10.1136\/thorax-2023-221274","relation":{},"ISSN":["0040-6376","1468-3296"],"issn-type":[{"value":"0040-6376","type":"print"},{"value":"1468-3296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,15]]}}}